Handelsavisen
prelaunch
Companies Healthcare MAIA.K
MA
MAIA.K NYSE Biotechnology & Medical Research

Maia Biotechnology Inc

$1,26
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
76,4M USD
P/E
EV / Rev
Div yield
Op margin
ROE
139,9 %
Net margin
Debt / equity
0,00
Beta
52w range
Volume
11
Day range
Prev close
$1,31
Open
Next earnings
2026-10-28
Ex-dividend
TR 1Y
About

Maia Biotechnology Inc is a biotechnology company focused on healthcare diagnostics, developing and commercializing innovative diagnostic solutions to improve patient outcomes.

Business. Maia Biotechnology Inc (MAIA.K) is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm is headquartered in the United States and is primarily listed on the New York Stock Exchange. Specific details regarding operating segments and geographic revenue mix are not available.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityHealthcare Diagnostics
Generated · model-assisted
Sell-side consensus
BUY1 analysts
1 buy0 hold0 sell
Avg 12m price target12,13

Analyst recommendations

1 analysts · consensus Buy
Buy1
Hold0
Sell0
12-month price target
12,13
Consensus of sell-side coverage.
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
1 analysts · indicative
Ownership
Geode Capital Management, L.L.C.
largest disclosed fund holder
Profitability
139,9 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning MAIA.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to MAIA.K. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Maia Biotechnology Inc (MAIA.K) is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm is headquartered in the United States and is primarily listed on the New York Stock Exchange. Specific details regarding operating segments and geographic revenue mix are not available.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryBiotechnology & Medical Research
    ActivityHealthcare Diagnostics
    AI synthesis
    GENERATED

    Maia Biotechnology Inc has a negative equity position of -$5.76 million and a market cap of $82.51 million, indicating a high degree of financial leverage and a speculative valuation. The company's liquidity position is characterized by a current ratio of 1.77, suggesting it can cover its short-term liabilities with its current assets, but its total liabilities of $14.48 million exceed its total assets of $8.72 million, indicating a net liability position.

    The company's profitability is negative, with a net loss of $8.07 million and an operating loss of $3.95 million. Its return on equity is 1.3994, which is unusually high given the negative equity, and its return on assets is -0.9256, indicating poor asset utilization. These metrics are not directly comparable to industry medians due to the absence of industry_config data for this company.

    Maia Biotechnology Inc's revenue concentration and geographic exposure are not disclosed in the available data. The company does not provide segment-specific financials, and its operating cash flow of -$3.59 million suggests it is not generating positive cash from operations. The absence of long-term debt indicates the company is not leveraging debt to fund operations, but this also suggests limited financial flexibility.

    The company's growth trajectory is not quantified in the available data, but its negative operating and net income suggest it is not currently profitable. Analysts have assigned a mean price target of $12.13, with a median of $12.13 and a high of $14.00, indicating a potential upside from the current market price of $1.36. However, the absence of revenue history makes it difficult to assess the company's growth potential.

    The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company's dilution potential is low, and its capital structure does not show signs of recent or planned equity issuance. The absence of long-term debt and the low dilution risk suggest the company is not currently under financial pressure to raise additional capital.

    Recent events and filings for Maia Biotechnology Inc are not detailed in the available data. The company's financial snapshot does not include specific events or transcripts, and the risk assessment does not flag any recent developments that would impact its financial position. The absence of detailed recent events makes it difficult to assess the company's current strategic direction or operational performance.

    Key takeaways
    • Maia Biotechnology Inc is a speculative biotechnology company with a negative equity position and no long-term debt.
    • The company's current ratio of 1.77 suggests it can cover its short-term liabilities, but its total liabilities exceed its total assets.
    • Analysts have assigned a mean price target of $12.13, indicating a potential upside from the current market price of $1.36.
    • The company's profitability is negative, with a net loss of $8.07 million and an operating loss of $3.95 million.
    • Maia Biotechnology Inc has low liquidity and dilution risk, with no immediate filing-based flags detected.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Quarterly
    Annual
    QUARTERLYFiled 2026-03-23
    Q4 2025 · Quarter highlights
    Open report →

    Operating income +13,7% YoY; Net income −1,6% YoY.

    Revenue
    Operating income-$4.3M+13,7 % YoY
    Net income-$3.6M−1,6 % YoY
    Free cash flow
    EPS
    Operating cash flow-$18.8M−20,0 % YoY
    Financials
    Income statement
    Revenue
    Gross profit
    Operating income-$4.3M
    Net income-$3.6M
    Balance sheet
    Total assets$9.7M
    Total liabilities$7.3M
    Total equity$2.4M
    Cash & equivalents
    Long-term debt$0.00
    Cash flow
    Operating cash flow-$18.8M
    CapEx
    Free cash flow
    SBC
    Highlights
    • Operating income +13,7% YoY
    • Net income −1,6% YoY

    Valuation TTM

    Market price
    $1,26
    Market cap
    $82.5M
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    -$5.8M
    Net cash
    Current ratio
    1.8
    Debt / equity
    0.0
    ROA
    -92.6%
    ROE
    1.4%
    Cash conversion
    44.0%
    CapEx / revenue
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    Business relationships3 disclosed relationships · 1 type · extracted from filings & disclosures
    Partners3
    Beone Medicines LtdONC.OPartner95%Source ↗

    Supply chain

    Vendors → MAIA ↔ Partners → Customers · click any node to drill
    VENDORSPARTNERSCUSTOMERSMAIAMAIAMaia Biotechnology Inc3 entitiesBeone Medicines LtdUnclassifiedUSREGENERON PHARMACEUTICDiversified PharmaceuticUSRoche Holding AGSemiconductorsCA
    3 mentions in 10-K0 from corporate websites0 from news dispatches
    Updated 2026-06-24

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    -0,69
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    1
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-16 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate-0,69
    Revenueno estimateno estimate0 USD
    Operating incomeno estimateno estimate-33,2M USD
    Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution1 analysts
    Strong buy0
    Buy1
    Hold0
    Sell0
    Strong sell0
    12-month price target$12,13 · Median $12,13
    Low $10,27High $14,00
    Operating income · consensus-33,2M USD
    EPS surprise
    −1,4 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$10,27
    Mean$12,13
    Median$12,13
    High$14,00
    Spot$1,26
    +863.1 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    ROE139,9 %Best in class
    D/E0,00Above median
    Cash Conv0,44Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    Derivative transactions

    Net acquired 3 004 527 sh18 grants9 insiders
    • Gryaznov SergeiChief Scientific Officer · Stock Options → Common StockAcquired 400 000 @ $1,39grant · 2026-05-29
    • Vitoc VladDirector, Chief Executive Officer, 10% owner · Stock Options → Common StockAcquired 800 000 @ $1,39grant · 2026-05-29
    • Himmelreich Jeffrey CHead of Finance · Stock Options → Common StockAcquired 60 000 @ $1,39grant · 2026-05-29
    • Gryaznov SergeiChief Scientific Officer · Stock Options → Common StockAcquired 400 000 @ $1,28grant · 2026-04-10
    • Himmelreich Jeffrey CHead of Finance · Stock Options → Common StockAcquired 30 000 @ $1,28grant · 2026-04-10
    • Vitoc VladDirector, Chief Executive Officer, 10% owner · Stock Options → Common StockAcquired 800 000 @ $1,28grant · 2026-04-10
    • CHAOUKI STEVEN MDirector · Stock Options → Common StockAcquired 27 907 @ $1,40grant · 2026-03-31
    • Guerrero RamiroDirector · Stock Options → Common StockAcquired 27 258 @ $1,40grant · 2026-03-31
    • Louie Ngar YeeDirector · Stock Options → Common StockAcquired 33 748 @ $1,40grant · 2026-03-31
    • Luput CristianDirector · Stock Options → Common StockAcquired 28 556 @ $1,40grant · 2026-03-31
    • Theagene Jean-ManasseDirector · Stock Options → Common StockAcquired 27 258 @ $1,40grant · 2026-03-31
    • Smith StanDirector · Stock Options → Common StockAcquired 33 099 @ $1,40grant · 2026-03-31
    • Theagene Jean-ManasseDirector · Options → Common StockAcquired 24 060 @ $1,53grant · 2025-12-31
    • Smith StanDirector · Options → Common StockAcquired 29 216 @ $1,53grant · 2025-12-31
    • Luput CristianDirector · Options → Common StockAcquired 25 206 @ $1,53grant · 2025-12-31
    • Louie Ngar YeeDirector · Options → Common StockAcquired 29 789 @ $1,53grant · 2025-12-31
    • Guerrero RamiroDirector · Options → Common StockAcquired 24 060 @ $1,53grant · 2025-12-31
    • CHAOUKI STEVEN MDirector · Options → Common StockAcquired 24 633 @ $1,53grant · 2025-12-31
    • Louie Ngar YeeDirector · Stock Options → Common StockAcquired 81 699 @ $1,36purchase · 2025-12-22
    • Smith StanDirector · Stock Options → Common StockAcquired 57 189 @ $1,36purchase · 2025-12-22
    • CHAOUKI STEVEN MDirector · Stock Options → Common StockAcquired 40 849 @ $1,36purchase · 2025-12-22

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • Maia Biotechnology Inc Market data — financials · 2026-05-28
    • Maia Biotechnology Inc Market data — analyst estimates · 2026-05-28

    Ownership & reference

    Top holders

    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$1M
    • Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$2M
    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$0M
    • BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$0M
    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$0M
    • JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$0M
    • FMR LLCInstitutional Investor · as of 2026-03-310,00 %$0M

    Insider activity

    Net buying6 buys · 0 sellsnet $424K5 insiders · last 365d
    • Gryaznov SergeiChief Scientific Officer · Common StockBought 2 000 @ $1,34$3K · 2026-06-01
    • Vitoc VladDirector, Chief Executive Officer, 10% owner · Common StockBought 72 700 @ $1,39$101K · 2026-06-01
    • Smith StanDirector · Common StockBought 75 000 @ $1,34$100K · 2026-06-01
    • Smith StanDirector · Common StockBought 57 189 @ $1,22$70K · 2025-12-22
    • CHAOUKI STEVEN MDirector · Common StockBought 40 849 @ $1,22$50K · 2025-12-22
    • Louie Ngar YeeDirector · Common StockBought 81 699 @ $1,22$100K · 2025-12-22

    Short positioning

    2.9Mshares short-14.5% vs prior
    4.08days to cover
    23.1%short of daily vol
    1.6Kfails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    MAIA.KCanonical
    NYSE · USD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.
    Relationship graph
    MAIAONC.OREGN.OROG.TOBiotechnology
    This companySectorPartners

    Evidence & claims

    From filings & derived data
    • Debt-to-equity (FY 2025-12-31): 3.08xDerived (calculated)
    • Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -34.6%Derived (calculated)
    • EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 33.3%Derived (calculated)
    • Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -20.0%Derived (calculated)
    • EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 33.3%Derived (calculated)
    • Net income (YoY) (2025-12-31 vs 2024-12-31): 3.7%Derived (calculated)
    • Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 12.4%Derived (calculated)
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): -4.4%Derived (calculated)
    • R&D expense (YoY) (2025-12-31 vs 2024-12-31): -95.5%Derived (calculated)
    • Return on equity (FY 2025-12-31): -942.7%Derived (calculated)
    • Return on assets (FY 2025-12-31): -230.8%Derived (calculated)
    • Current ratio (FY 2025-12-31): 1.66xDerived (calculated)
    • Operating income (YoY) (2025-12-31 vs 2024-12-31): -43.1%Derived (calculated)
    • Pre-tax income (annual): USD -22.39MSEC XBRL filing
    • Total operating expenses (annual): USD 24.27MSEC XBRL filing
    • Total liabilities (annual): USD 7.33MSEC XBRL filing
    • Current liabilities (annual): USD 5.84MSEC XBRL filing
    • Cash & equivalents (annual): USD 0SEC XBRL filing
    • EPS (basic) (annual): USD-PER-SHARES -1SEC XBRL filing
    • Operating income (annual): USD -24.27MSEC XBRL filing
    • EPS (diluted) (annual): USD-PER-SHARES -1SEC XBRL filing
    • R&D expense (annual): USD 453.75KSEC XBRL filing
    • Shareholders' equity (annual): USD 2.38MSEC XBRL filing
    • Current assets (annual): USD 9.7MSEC XBRL filing
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: insider_flow_signal (90d)
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-01 00:00 UTCINSIDER3 insider transactions — 2026-06 · net buy $204k
    2026-06-01INSIDERGryaznov Sergei bought 2.0k sh — Chief Scientific Officer ~$3k
    2026-06-01INSIDERVitoc Vlad bought 72.7k sh — Director, Chief Executive Officer, 10% owner ~$101k
    2026-06-01INSIDERSmith Stan bought 75.0k sh — Director ~$100k
    2026-05-29 00:00 UTCINSIDER3 insider transactions — 2026-05 3 derivative
    2026-05-29INSIDERHimmelreich Jeffrey C acquired 60.0k sh Stock Options — Head of Finance
    2026-05-29INSIDERGryaznov Sergei acquired 400.0k sh Stock Options — Chief Scientific Officer
    2026-05-29INSIDERVitoc Vlad acquired 800.0k sh Stock Options — Director, Chief Executive Officer, 10% owner
    2026-05-22FILING8-K filing →
    2026-05-14FILING8-K filing →
    2026-05-14FILING424B5 filing →
    2026-05-11FILING10-Q filing →
    2026-04-16FILING8-K filing →
    2026-04-10 00:00 UTCINSIDER3 insider transactions — 2026-04 3 derivative
    2026-04-10INSIDERVitoc Vlad acquired 800.0k sh Stock Options — Director, Chief Executive Officer, 10% owner
    2026-04-10INSIDERHimmelreich Jeffrey C acquired 30.0k sh Stock Options — Head of Finance
    2026-04-10INSIDERGryaznov Sergei acquired 400.0k sh Stock Options — Chief Scientific Officer
    2026-04-08FILING8-K filing →
    2026-04-07FILINGDEF 14A filing →
    2026-04-02FILING8-K filing →
    2026-03-31 00:00 UTCINSIDER6 insider transactions — 2026-03 6 derivative
    2026-03-31FILING8-K filing →
    2026-03-31INSIDERTheagene Jean-Manasse acquired 27.3k sh Stock Options — Director
    2026-03-31INSIDERCHAOUKI STEVEN M acquired 27.9k sh Stock Options — Director
    2026-03-31INSIDERLouie Ngar Yee acquired 33.7k sh Stock Options — Director
    2026-03-31INSIDERSmith Stan acquired 33.1k sh Stock Options — Director
    2026-03-31INSIDERLuput Cristian acquired 28.6k sh Stock Options — Director
    2026-03-31INSIDERGuerrero Ramiro acquired 27.3k sh Stock Options — Director
    2026-03-27FILING8-K filing →
    2026-03-23 09:02 UTCEARNINGSQuarterly results — Q4 2025 Net USD -3.6M
    2026-03-23 09:02 UTCEARNINGSAnnual results — FY 2026 Net USD -22.4M
    2026-03-23FILING10-K filing →
    2026-03-04FILING8-K filing →
    2025-12-31 00:00 UTCINSIDER12 insider transactions — 2025-12 · net buy $220k 9 derivative
    2025-12-31INSIDERTheagene Jean-Manasse acquired 24.1k sh Options — Director
    2025-12-31INSIDERLuput Cristian acquired 25.2k sh Options — Director
    2025-12-31INSIDERLouie Ngar Yee acquired 29.8k sh Options — Director
    Showing the 40 most recent of 61 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage